If you made any changes in Pure these will be visible here soon.

Personal profile


  • 2005-2013 Ph.D., Degree in Institute of BioMedical Informatics, National YangMing University
  • 1998-2000 M.S., National Defense Medical Center
  • 1994-1998 B.S., Department of Life Sciences, National Chung Hsing University

Research Interests

  • Epigenomics


  • Assistant Professor, Department of Gynecology and Obstetrics, School of Medicine, Taipei Medical University

Fingerprint Dive into the research topics where Rui-Lan Huang is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 26 Similar Profiles
Methylation Medicine & Life Sciences
DNA Methylation Medicine & Life Sciences
Ovarian Neoplasms Medicine & Life Sciences
Uterine Cervical Neoplasms Medicine & Life Sciences
Epigenomics Medicine & Life Sciences
Genes Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Biomarkers Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2015 2019

Epigenetic Characterization of Ovarian Cancer Initiating Cells

Lai, H. & Huang, R.


Project: A - Government Institutiona - National Health Research Institutes

Research Output 2001 2019

  • 903 Citations
  • 16 h-Index
  • 58 Article
  • 1 Chapter
2 Citations (Scopus)

E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness

Cheng, F. H. C., Lin, H. Y., Hwang, T. W., Chen, Y. C., Huang, R. L., Chang, C. B., Yang, W., Lin, R. I., Lin, C. W., Chen, G. C. W., Mai, S. Y., Lin, J. M. J., Chuang, Y. M., Chou, J. L., Kuo, L. W., Li, C., Cheng, A. S. L., Lai, H. C., Wu, S. F., Tsai, J. C. & 1 others, Chan, M. W. Y., Jan 1 2019, (Accepted/In press) In : Cancer Science.

Research output: Contribution to journalArticle

Ovarian Neoplasms
E2F6 Transcription Factor
2 Citations (Scopus)

TET1 promotes 5hmC-dependent stemness, and inhibits a 5hmC-independent epithelial-mesenchymal transition, in cervical precancerous lesions

Su, P. H., Hsu, Y. W., Huang, R. L., Chen, L. Y., Chao, T. K., Liao, C. C., Chen, C. W., Wu, T. I., Mao, S. P., Balch, C. & Lai, H. C., May 28 2019, In : Cancer Letters. 450, p. 53-62 10 p.

Research output: Contribution to journalArticle

Epithelial-Mesenchymal Transition
Gene Silencing
1 Citation (Scopus)

TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target

Chen, L. Y., Huang, R. L., Chan, M. W. Y., Yan, P. S., Huang, T. S., Wu, R. C., Suryo Rahmanto, Y., Su, P. H., Weng, Y. C., Chou, J. L., Chao, T. K., Wang, Y. C., Shih, I. M. & Lai, H. C., Jan 1 2019, In : Journal of Pathology.

Research output: Contribution to journalArticle

Casein Kinase II
Precision Medicine
Operative Time
Length of Stay
1 Citation (Scopus)

Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors

Liew, P. L., Huang, R. L., Weng, Y. C., Fang, C. L., Hui-Ming Huang, T. & Lai, H. C., Jul 15 2018, In : International Journal of Cancer. 143, 2, p. 355-367 13 p.

Research output: Contribution to journalArticle

Mucinous Adenocarcinoma
Proteasome Inhibitors
Gastrointestinal Neoplasms
Ovarian epithelial cancer